Shaimaa ELShebiney

Dr. Shaimaa ELShebiney

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Neurochemistry International
Verified
Journal Article
Closed access
WKWagdy Khalil
Wagdy Khalil
NANaglaa Assaf
Naglaa Assaf
SEShaimaa ELShebiney
Shaimaa ELShebiney
NSNeveen Salem
Neveen Salem

6 April 2017 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
AMAmira Mohamed Mohsen
Amira Mohamed Mohsen
MAMona Mahmoud AbouSamra
Mona Mahmoud AbouSamra
SEShaimaa ELShebiney
Shaimaa ELShebiney
This study was designed to investigate the potency of niosomes, for glimepiride (GLM) encapsulation, aiming at enhancing its oral bioavailability and hypoglycemic efficacy. Niosomes containing nonionic surfactants (NIS) were prepared by thin film hydration technique and characterized. In-vitro release study was performed using a dialysis technique. In-vivo pharmacodynamic studies, as well as pharmacokinetic evaluation were performed on alloxan-induced diabetic rats. GLM niosomes exhibited high-entrapment efficiency percentages (E.E. %) up to 98.70% and a particle size diameter ranging from 186.8 ± 18.69 to 797.7 ± 12.45 nm, with negatively charged zeta potential (ZP). Different GLM niosomal formulation showed retarded in vitro release, compared to free drug. In-vivo studies revealed the superiority of GLM niosomes in lowering blood glucose level (BGL) and in maintaining a therapeutic level of GLM for a longer period of time, as compared to free drug and market product. There was no significant difference between mean plasma AUC0-48 hr of GLM-loaded niosomes and that of market product. GLM-loaded niosomes exhibited seven-fold enhancement in relative bioavailability in comparison with free drug. These findings reinforce the potential use of niosomes for enhancing the oral bioavailability and prolonged delivery of GLM via oral administration.

1 December 2018 in Materials Science and Engineering: C
Verified
Journal Article
Open access
KTKhairy M. Tohamy
Khairy M. Tohamy
ISIslam E. Soliman
Islam E. Soliman
Mostafa MabroukMostafa Mabrouk
Mostafa Mabrouk
SEShaimaa ELShebiney
Shaimaa ELShebiney
HBHanan H. Beherei
Hanan H. Beherei
Diganta Bhusan DasDiganta Bhusan Das
Diganta Bhusan Das
The main goal of this study was to produce a novel porous scaffold for rapid in vivo bone healing behavior. Lyophilization technique was used to produce this highly porous hybrid scaffold from Na-alginate (S) and hydroxyethylcellulose (HEC) impregnated with different concentration of hydroxyapatite (HA). After cross-linking the scaffolds, their incubation was carried out in simulated body fluid (SBF) for 4 weeks at 37 °C to investigate their bioactivity. A number of techniques were employed (e.g., XRD, FTIR, SEM, EDX, and texture analyzer) to characterize the designed scaffolds. It was observed that the mechanical properties of the scaffolds increase deformation energy (182 ± 16 J/m3) and rigidity gradient (19.44 ± 0.85 Pa) after loading with HA. Furthermore, the scaffolds were implanted in femur critical size defects (2 mm) of adult male Wistar rats for 6 weeks. In vitro and in vivo analyses demonstrated impressive bioactivity and biocompatibility for the prepared scaffolds, especially those containing HA. Based on the obtained results we conclude that the designed scaffolds are promising solutions for bone regeneration applications.

15 April 2018 in Journal of Biomedical Materials Research Part B: Applied Biomaterials
Verified
Journal Article
Closed access
PDF file
Mostafa MabroukMostafa Mabrouk
Mostafa Mabrouk
SEShaimaa ELShebiney
Shaimaa ELShebiney
SKSayed H. Kenawy
Sayed H. Kenawy
GEGehan T. El‐Bassyouni
Gehan T. El‐Bassyouni
EHEsmat Ma Hamzawy
Esmat Ma Hamzawy

17 September 2019 in Molecules
Verified
Journal Article
Open access
PDF file
Mohamed FaragMohamed Farag
Mohamed Farag
AOAsmaa M. Otify
Asmaa M. Otify
AEAly M. El-Sayed
Aly M. El-Sayed
CMCamilia G. Michel
Camilia G. Michel
SEShaimaa ELShebiney
Shaimaa ELShebiney
LWLudger A. Wessjohann
Ludger A. Wessjohann
Interest in developing coffee substitutes is on the rise, to minimizing its health side effects. In the Middle East, date palm (Phoenix dactylifera L.) pits are often used as a coffee substitute post roasting. In this study, commercially-roasted date pit products, along with unroasted and home-prepared roasted date pits, were subjected to analyses for their metabolite composition, and neuropharmacological evaluation in mice. Headspace SPME-GCMS and GCMS post silylation were employed for characterizing its volatile and non-volatile metabolite profile. For comparison to roasted coffee, coffee product was also included. There is evidence that some commercial date pit products appear to contain undeclared additives. SPME headspace analysis revealed the abundance of furans, pyrans, terpenoids and sulfur compounds in roasted date pits, whereas pyrroles and caffeine were absent. GCMS-post silylation employed for primary metabolite profiling revealed fatty acids’ enrichment in roasted pits versus sugars’ abundance in coffee. Biological investigations affirmed that date pit showed safer margin than coffee from its LD50, albeit it exhibits no CNS stimulant properties. This study provides the first insight into the roasting impact on the date pit through its metabolome and its neuropharmacological aspects to rationalize its use as a coffee substitute.

22 February 2018 in Inflammopharmacology
Verified
Journal Article
Closed access
PDF file
NSNeveen Salem
Neveen Salem
MEMarwa El-Shamarka
Marwa El-Shamarka
YKYasser Khadrawy
Yasser Khadrawy
SEShaimaa ELShebiney
Shaimaa ELShebiney